FIELD: biotechnology.
SUBSTANCE: presented is using an inhibiting MASP-2 antibody or an antigen-binding fragment thereof, which inhibits MASP-2-dependent complement activation, for preparing a drug for treating a subject suffering from catastrophic antiphospholipid syndrome.
EFFECT: invention provides inhibition of cell damage associated with MASP-2 mediated activation of the alternative complement pathway, keeping the immune system component representing the classical (C1q-dependent) pathway intact.
18 cl, 78 dwg, 42 tbl, 43 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2014 |
|
RU2718850C2 |
| METHODS OF TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION | 2012 |
|
RU2743409C2 |
| COMPOSITIONS FOR INHIBITING MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2017 |
|
RU2725958C2 |
| PHARMACEUTICAL COMPOSITION FOR USE IN TREATING OR PREVENTING C5-RELATED DISEASE, AND METHOD OF TREATING OR PREVENTING C5-RELATED DISEASE | 2019 |
|
RU2832946C2 |
| ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE | 2017 |
|
RU2789788C2 |
| PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE | 2019 |
|
RU2789389C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
| DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING ANTI-C5 CROVALIMAB ANTIBODY | 2020 |
|
RU2832188C2 |
| MONOVALENT ANTIBODIES TO PROPERDIN AND FRAGMENTS OF ANTIBODIES | 2018 |
|
RU2790103C2 |
